English
Back
Open Account
牛牛名人追蹤
wrote a column · May 13 13:36 ·

Tracking Cathie Wood: Continued bet on gene-editing leader NTLA, took profits on TWST and CDNA

Eastern Time on Tuesday, the three major U.S. stock indexes closed mixed; chip stocks generally retreated, and weakness in tech stocks weighed on the Nasdaq, causing it to lead declines. However, the healthcare sector remained solid due to Humana’s strong performance, which also helped the Dow maintain its upward momentum.
Against this backdrop, 'Woodie' (Cathie Wood) has continued to increase her position in the gene-editing leader $Intellia Therapeutics (NTLA.US)$ ; while on the sell side, she targeted synthetic biology stocks that had already reached high gains recently $Twist Bioscience (TWST.US)$ , as well as the transplantation diagnostic target $CareDx (CDNA.US)$ Take profit at high levels.
US Eastern Time Tuesday, the three major U.S. stock indexes closed mixed, with chip stocks generally retreating; tech stocks weakened, dragging down the Nasdaq, but the healthcare sector performed strongly driven by Humana's surge, helping the Dow maintain its upward trend. Against this backdrop, Cathie Wood continued to increase her position in the gene-editing leader $Intellia Therapeutics (NTLA.US)$ ; on the selling side, she took profits on the synthetic biology stock $Twist Bioscience (TWST.US)$ and the transplant diagnostics stock $CareDx (CDNA.US)$ , both of which had reached recent high gains. Buying Focus: Sticking to Gene-Editing Strategy – Aggressively bought $Intellia Therapeutics (NTLA.US)$ 40,000 shares.NTLA, a high-weight gene-editing target in ARK's portfolio, is currently on the eve of releasing key clinical data. The market expects its CRISPR in vivo editing technology to achieve landmark progress in the treatment of genetic diseases. – Slightly increased holdings by $Natera (NTRA.US)$ 4,310 shares.NTRA continues to consolidate its leading position in the field of oncology liquid biopsy. The company’s recent earnings report showed better-than-expected growth in test volumes. Sell-side direction: Taking profits at highs – Reduce holdings $Twist Bioscience (TWST.US)$56,400 shares...
Buy direction: Maintain gene editing layout
– Aggressively bought $Intellia Therapeutics (NTLA.US)$ 40,000 shares.NTLA, a gene-editing target with extremely high weighting in the ARK portfolio, is currently on the eve of releasing critical clinical data. The market expects its CRISPR in vivo editing technology to achieve landmark progress in treating genetic diseases.
– Slightly increase holdings simultaneously $Natera (NTRA.US)$ 4,310 shares.NTRA continues to consolidate its leading position in the field of oncology liquid biopsies. The company's recently announced earnings show that its testing volume growth has exceeded expectations.
Sell direction: Take profit at high levels
– Reduce holdings $Twist Bioscience (TWST.US)$56,400 shares.TWST has been the star of the recent synthetic biology sector, with its stock price recording an astonishing increase over the past few weeks. ARK's reduction in holdings does not indicate a lack of confidence in TWST’s technology but rather represents a typical 'rotation at highs.' TWST still faces pressure on gross margins and risks from long-term R&D investments. ARK chose to cash out at this high point to reallocate liquidity, transferring funds precisely to NTLA, which appears to have better 'value for money.'
– Continued reduction $CareDx (CDNA.US)$ of 14,400 shares.The continued reduction in CareDx reflects ARK's reassessment of the competitive landscape in the transplant care space. With increasing pricing pressures in the industry, this once highly anticipated diagnostics company is gradually losing its weight in ARK's core portfolio.
Want to keep up with the big players' moves?
Futubull [Opportunities page] Now featuring the ability to track portfolios of renowned investors! Choose from multiple celebrity holdings, follow the investment strategies of top players with one click, accurately target high-quality stocks, and invest with greater confidence!
US Eastern Time Tuesday, the three major U.S. stock indexes closed mixed, with chip stocks generally retreating; tech stocks weakened, dragging down the Nasdaq, but the healthcare sector performed strongly driven by Humana's surge, helping the Dow maintain its upward trend. Against this backdrop, Cathie Wood continued to increase her position in the gene-editing leader $Intellia Therapeutics (NTLA.US)$ ; on the selling side, she took profits on the synthetic biology stock $Twist Bioscience (TWST.US)$ and the transplant diagnostics stock $CareDx (CDNA.US)$ , both of which had reached recent high gains. Buying Focus: Sticking to Gene-Editing Strategy – Aggressively bought $Intellia Therapeutics (NTLA.US)$ 40,000 shares.NTLA, a high-weight gene-editing target in ARK's portfolio, is currently on the eve of releasing key clinical data. The market expects its CRISPR in vivo editing technology to achieve landmark progress in the treatment of genetic diseases. – Slightly increased holdings by $Natera (NTRA.US)$ 4,310 shares.NTRA continues to consolidate its leading position in the field of oncology liquid biopsy. The company’s recent earnings report showed better-than-expected growth in test volumes. Sell-side direction: Taking profits at highs – Reduce holdings $Twist Bioscience (TWST.US)$56,400 shares...
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
11
104K Views
Report
Comment (1)
Write a Comment...
1
11
12